EGFR and neoplasm: Ground-glass opacity (GGO) was frequently observed in patients with EGFR-positive tumors, and the proportion of GGO within the tumor was significantly greater in patients with 21L858R mutations compared to those with 19Del deletions and those with the wild-type gene (32, 33).